{"id":"W1968949098","doi":"10.1016/s0140-6736(10)60284-x","title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":906,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"University of California, San Diego","keywords":"Medicine; Placebo; Familial hypercholesterolemia; Internal medicine; Apolipoprotein B; Gastroenterology; Clinical endpoint; Cholesterol; Clinical trial; Intention-to-treat analysis; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02398229010341136,"score_gpt":0.2774385225148751,"score_spread":0.2534562324114638,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}